Generic Micardis Availability

Micardis is a brand name of telmisartan, approved by the FDA in the following formulation(s):

MICARDIS (telmisartan - tablet;oral)

Has a generic version of Micardis been approved?

A generic version of Micardis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Micardis and have been approved by the FDA:

telmisartan tablet;oral

  • Manufacturer: WATSON LABS
    Approval date: January 8, 2014
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Micardis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Benzimidazoles useful as angiotensin-11 antagonists
    Patent 5,591,762
    Issued: January 7, 1997
    Inventor(s): Hauel; Norbert & Narr, deceased; Berthold & Ries; Uwe & van Meel; Jacobus C. A. & Wienen; Wolfgang & Entzeroth; Michael
    Assignee(s): Dr. Karl Thomae GmbH
    Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
    Patent expiration dates:
    • January 7, 2014
    • January 7, 2014
      Drug substance
      Drug product
  • Polymorphs of telmisartan
    Patent 6,358,986
    Issued: March 19, 2002
    Inventor(s): Heinrich; Schneider
    Assignee(s): Boehringer Ingelheim Pharma KG
    The invention relates to polymorphs of 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.
    Patent expiration dates:
    • January 10, 2020
  • Use of inhibitors of the renin-angiotensin system
    Patent 7,998,953
    Issued: August 16, 2011
    Inventor(s): Montgomery; Hugh Edward & Martin; John Francis & Erusalimsky; Jorge Daniel
    Assignee(s): Ark Therapeutics Group, p.l.c.
    It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
    Patent expiration dates:
    • June 6, 2020
  • Use of inhibitors of the renin-angiotensin system
    Patent 8,003,679
    Issued: August 23, 2011
    Inventor(s): Montgomery; Hugh Edward & Martin; John Francis & Erusalimsky; Jorge Daniel
    Assignee(s): ArkTherapeutics Group, plc
    Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.
    Patent expiration dates:
    • October 6, 2022


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.